agreements

R&D

January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.